Search Results - "Godwin, John E."

Age and acute myeloid leukemia by Appelbaum, Frederick R., Gundacker, Holly, Head, David R., Slovak, Marilyn L., Willman, Cheryl L., Godwin, John E., Anderson, Jeanne E., Petersdorf, Stephen H.

“…We conducted a retrospective analysis of 968 adults with acute myeloid leukemia (AML) on 5 recent Southwest Oncology Group trials to understand how the nature…”
Get full text

Improved outcomes with "7+3" induction chemotherapy for acute myeloid leukemia over the past four decades: analysis of SWOG trial data by Othus, Megan, Garcia-Manero, Guillermo, Godwin, John E, Weick, James K, Appelbaum, Frederick R, Erba, Harry P, Estey, Elihu H

“…We have previously shown that complete response (CR) rates and overall survival of patients with acute myeloid leukemia have improved since the 1980s. However,…”
Get full text

Epidemiology of dermatophytes among primary school children in Calabar, Nigeria by Okpo, Ekomobong A., Andy, Iniobong E, John, Godwin E, Chinyeaka, Rosemary C.

“…Background & Aims: Children are more susceptible to dermatophytes due to different predisposing factors, such as under developed immune system and high…”
Get full text

Histone Deacetylase Inhibitor Romidepsin Has Differential Activity in Core Binding Factor Acute Myeloid Leukemia by ODENIKE, Olatoyosi M, ALKAN, Serhan, STIFF, Patrick, WRIGHT, John, LARSON, Richard A, STOCK, Wendy, SHER, Dorie, GODWIN, John E, DEZHENG HUO, BRANDT, Stephen J, GREEN, Margaret, JINGPING XIE, YANMING ZHANG, VESOLE, David H

“…Purpose: Recruitment of histone deacetylases (HDAC) is a mechanism of transcriptional repression implicated in the differentiation block in acute myeloid…”
Get full text

AML risk stratification models utilizing ELN-2017 guidelines and additional prognostic factors: a SWOG report by Pogosova-Agadjanyan, Era L, Moseley, Anna, Othus, Megan, Appelbaum, Frederick R, Chauncey, Thomas R, Chen, I-Ming L, Erba, Harry P, Godwin, John E, Jenkins, Isaac C, Fang, Min, Huynh, Mike, Kopecky, Kenneth J, List, Alan F, Naru, Jasmine, Radich, Jerald P, Stevens, Emily, Willborg, Brooke E, Willman, Cheryl L, Wood, Brent L, Zhang, Qing, Meshinchi, Soheil, Stirewalt, Derek L

“…The recently updated European LeukemiaNet risk stratification guidelines combine cytogenetic abnormalities and genetic mutations to provide the means to triage…”
Get full text

Association between early promoter-specific DNA methylation changes and outcome in older acute myeloid leukemia patients by Achille, Nicholas J, Othus, Megan, Phelan, Kathleen, Zhang, Shubin, Cooper, Kathrine, Godwin, John E, Appelbaum, Frederick R, Radich, Jerald P, Erba, Harry P, Nand, Sucha, Zeleznik-Le, Nancy J

“…Highlights • Very early peripheral blood promoter demethylation of some genes predict response. • Global DNA methylation decreased by one month in older AML…”
Get full text

Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study by Sehgal, Alison, Hoda, Daanish, Riedell, Peter A, Ghosh, Nilanjan, Hamadani, Mehdi, Hildebrandt, Gerhard C, Godwin, John E, Reagan, Patrick M, Wagner-Johnston, Nina, Essell, James, Nath, Rajneesh, Solomon, Scott R, Champion, Rebecca, Licitra, Edward, Fanning, Suzanne, Gupta, Neel, Dubowy, Ronald, D'Andrea, Aleco, Wang, Lei, Ogasawara, Ken, Thorpe, Jerill, Gordon, Leo I

“…Patients with relapsed or refractory large B-cell lymphoma after first-line treatment who are not intended for haematopoietic stem-cell transplantation (HSCT)…”
Get full text

Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia by Uy, Geoffrey L., Aldoss, Ibrahim, Foster, Matthew C., Sayre, Peter H., Wieduwilt, Matthew J., Advani, Anjali S., Godwin, John E., Arellano, Martha L., Sweet, Kendra L., Emadi, Ashkan, Ravandi, Farhad, Erba, Harry P., Byrne, Michael, Michaelis, Laura, Topp, Max S., Vey, Norbert, Ciceri, Fabio, Carrabba, Matteo Giovanni, Paolini, Stefania, Huls, Gerwin A., Jongen-Lavrencic, Mojca, Wermke, Martin, Chevallier, Patrice, Gyan, Emmanuel, Récher, Christian, Stiff, Patrick J., Pettit, Kristen M., Löwenberg, Bob, Church, Sarah E., Anderson, Erica, Vadakekolathu, Jayakumar, Santaguida, Marianne, Rettig, Michael P., Muth, John, Curtis, Teia, Fehr, Erin, Guo, Kuo, Zhao, Jian, Bakkacha, Ouiam, Jacobs, Kenneth, Tran, Kathy, Kaminker, Patrick, Kostova, Maya, Bonvini, Ezio, Walter, Roland B., Davidson-Moncada, Jan K., Rutella, Sergio, DiPersio, John F.

“…Approximately 50% of acute myeloid leukemia (AML) patients do not respond to induction therapy (primary induction failure [PIF]) or relapse after <6 months…”
Get full text

Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance) by Byrd, John C., Ruppert, Amy S., Heerema, Nyla A., Halvorson, Alese E., Hoke, Eva, Smith, Mitchell R., Godwin, John E., Couban, Stephen, Fehniger, Todd A., Thirman, Michael J., Tallman, Martin S., Appelbaum, Frederick R., Stone, Richard M., Robinson, Sue, Chang, Julie E., Mandrekar, Sumithra J., Larson, Richard A.

“…Prior to novel targeted agents for chronic lymphocytic leukemia (CLL), the best chemoimmunotherapy regimen in patients with non-del(11q) disease was unclear…”
Get full text

A phase 1 study of triple‐targeted therapy with BRAF, MEK, and AKT inhibitors for patients with BRAF‐mutated cancers by Algazi, Alain P., Moon, James, Lao, Christopher D., Chmielowski, Bartosz, Kendra, Kari L., Lewis, Karl D., Gonzalez, Rene, Kim, Kevin, Godwin, John E., Curti, Brendan D., Latkovic‐Taber, Michaella, Lomeli, Shirley H., Gufford, Brandon T., Scumpia, Philip O., Lo, Roger S., Othus, Megan, Ribas, Antoni

“…Background Aberrant PI3K/AKT signaling in BRAF‐mutant cancers contributes to resistance to BRAF inhibitors. The authors examined dual MAPK and PI3K pathway…”
Get full text

A phase 2 trial of azacitidine and gemtuzumab ozogamicin therapy in older patients with acute myeloid leukemia by Nand, Sucha, Othus, Megan, Godwin, John E., Willman, Cheryl L., Norwood, Thomas H., Howard, Dianna S., Coutre, Steven E., Erba, Harry P., Appelbaum, Frederick R.

“…This trial tested the safety and efficacy of a regimen consisting of hydroxyurea followed by azacitidine, 75 mg/m2 for 7 days, and gemtuzumab ozogamicin, 3…”
Get full text

Second cycle remission achievement with 7+3 and survival in adults with newly diagnosed acute myeloid leukemia: analysis of recent SWOG trials by Othus, Megan, Estey, Elihu H., Garcia-Manero, Guillermo, Wood, Brent L., Stirewalt, Derek L., Godwin, John E., Weick, James K., Anderson, Jeanne E., Appelbaum, Frederick R., Erba, Harry P., Walter, Roland B.

Get full text

Association of immunophenotype with expression of topoisomerase II α and β in adult acute myeloid leukemia by Michelson, Andrew P., McDonough, Shannon, Willman, Cheryl L., Koegle, Eric R., Godwin, John E., Petersdorf, Stephen H., List, Alan F., Othus, Megan, Appelbaum, Frederick R., Radich, Jerald P., Ganapathi, Mahrukh K., Advani, Anjali S., Ganapathi, Ram N.

“…Anthracyclines used in the treatment of acute myelogenous leukemia (AML) inhibit the activity of the mammalian topoisomerase II (topo II) isoforms, topo II α…”
Get full text

Maintenance Decitabine (DAC) Improves Disease-Free (DFS) and Overall Survival (OS) after Intensive Therapy for Acute Myeloid Leukemia (AML) in Older Adults, Particularly in FLT3-ITD-Negative Patients: ECOG-ACRIN (E-A) E2906 Randomized Study by Foran, James M., Sun, Zhuoxin, Claxton, David F., Lazarus, Hillard M, Arber, Daniel A., Rowe, Jacob M., Paietta, Elisabeth, Racevskis, Janis, Altman, Jessica K., Luger, Selina M., Al-Kali, Aref, Zheng, Hong, Pratz, Keith W., Broun, Edward R., Powell, Bayard L, O'Dwyer, Kristen Marie, Godwin, John E., Ofran, Yishai, Litzow, Mark, Tallman, Martin S.

“…▪ Background: Relapse remains the most common cause of treatment failure after intensive induction and consolidation (CONS) therapy in older adults with AML…”
Get full text

Prognostic implications of the IDH1 synonymous SNP rs11554137 in pediatric and adult AML: a report from the Children's Oncology Group and SWOG by Ho, Phoenix A., Kopecky, Kenneth J., Alonzo, Todd A., Gerbing, Robert B., Miller, Kristen L., Kuhn, Julia, Zeng, Rong, Ries, Rhonda E., Raimondi, Susana C., Hirsch, Betsy A., Oehler, Vivian, Hurwitz, Craig A., Franklin, Janet L., Gamis, Alan S., Petersdorf, Stephen H., Anderson, Jeanne E., Godwin, John E., Reaman, Gregory H., Willman, Cheryl L., Bernstein, Irwin D., Radich, Jerald P., Appelbaum, Frederick R., Stirewalt, Derek L., Meshinchi, Soheil

“…IDH1 SNP rs11554137 was recently reported in association with poor prognosis in normal karyotype adult acute myeloid leukemia (AML). We aimed to determine the…”
Get full text

Impact of Specimen Heterogeneity on Biomarkers in Repository Samples from Patients with Acute Myeloid Leukemia: A SWOG Report by Pogosova-Agadjanyan, Era L, Moseley, Anna, Othus, Megan, Appelbaum, Frederick R, Chauncey, Thomas R, Chen, I-Ming L, Erba, Harry P, Godwin, John E, Fang, Min, Kopecky, Kenneth J, List, Alan F, Pogosov, Galina L, Radich, Jerald P, Willman, Cheryl L, Wood, Brent L, Meshinchi, Soheil, Stirewalt, Derek L

“…Current prognostic models for acute myeloid leukemia (AML) are inconsistent at predicting clinical outcomes for individual patients. Variability in the quality…”
Get more information

A model for prediction of FLT3‐ITD and NPM1 (without FLT3‐ITD) positivity in patients with newly diagnosed acute myeloid leukaemia by Ostronoff, Fabiana, Othus, Megan, Kantarjian, Hagop M., Meshinchi, Soheil, Ravandi, Farhad, Hendrie, Paul C., Faderl, Stefan, Becker, Pamela S., Cortes, Jorge E., Pagel, John M., Petersdorf, Stephen H., Godwin, John E., Willman, Cheryl L., Pierce, Sherry A., List, Alan F., Sandhu, Ravinder K., Walter, Roland B., Stirewalt, Derek L., Appelbaum, Frederick R., Estey, Elihu H.

Get full text

Schizoaffective disorder with missed diagnosis of acute porphyria: a case report and overview by Jain, Gaurav, Bennett, Jeffrey I, Resch, David S, Godwin, John E

“…Acute porphyrias are often misdiagnosed and most commonly present as atypical neuropsychiatric symptoms or acute abdominal pain. Clinicians should suspect…”
Get full text

Acute myeloid leukemia in the older patient by Godwin, John E., Smith, Scott E.

“…Acute myeloid leukemia (AML) is an extremely heterogeneous disorder. The biology of AML is incompletely understood, but much data indicates that older patients…”
Get full text

Phase II Trial of Low Dose, Subcutaneous Decitabine in Myelofibrosis by Odenike, Olatoyosi M, Godwin, John E., Van Besien, Koen, Huo, Dezheng, Sher, Dorie, Burke, Patrick, Smith, Scott E., Green, Margaret, Melnick, Julia, Wade, James L, Lester, Eric P., Klisovic, Rebecca B., Baer, Maria R., Larson, Richard A, Stock, Wendy

“…DNA hypermethylation of promoter-specific CpG islands has been implicated in the pathogenesis and progression of myelofibrosis (MF). We have evaluated…”
Get full text